Clinical Trials on Haemophilus Influenza Type b

Total 3978 results

Sanofi

Completed

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

Whooping Cough | Tetanus | Diphtheria | Polio | Haemophilus Influenzae Type b

United States
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b Infection

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Canada
GlaxoSmithKline

Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
GlaxoSmithKline

Completed

Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland
Beijing Center for Disease Control and Prevention

Completed

The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site

Healthy

China
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland
GlaxoSmithKline

Completed

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Germany
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b
GlaxoSmithKline

Completed

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Poliomyelitis Vaccines

Philippines
GlaxoSmithKline

Terminated

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Slovakia
GlaxoSmithKline

Completed

Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
GlaxoSmithKline

Completed

Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Italy, Sweden, Finland
Public Health England
Department of Health, United Kingdom; Institute of Child Health, London, England

Completed

Hepatitis B Vaccination in Infants (Infanrix)

Pneumococcal Disease | Meningococcal Disease | Diphtheria, Tetanus and Pertussis | Haemophilus Influenzae Serotype b Disease | Hepatitis b

United Kingdom
Sanwa BioTech Limited
Chinese University of Hong Kong; Prince of Wales Hospital, Shatin, Hong Kong

Not yet recruiting

Influenza A+B Test Kit Performance Study

Influenza Type B | Influenza Type A

Hong Kong
SAb Biotherapeutics, Inc.

Active, not recruiting

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Influenza | Influenza Type B | Influenza Type A

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

Pertussis | Tetanus | Diphtheria | Meningitis | Meningococcal Infection | Haemophilus Influenzae Serotype b (Hib)

United States, Puerto Rico
St. Jude Children's Research Hospital
National Institute of Allergy and Infectious Diseases (NIAID); The University...

Completed

Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China

Influenza Type B | Influenza Type A

China
GlaxoSmithKline

Completed

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Haemophilus Influenzae | Streptococcus Pneumoniae

Sweden
GlaxoSmithKline

Terminated

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Haemophilus Influenzae | Streptococcus Pneumoniae

Canada
Sanofi

Completed

Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

China
Novo Nordisk A/S

Completed

A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) (explorer™6)

Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

France, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
Sanofi

Completed

Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type B

Korea, Republic of
Vanderbilt University Medical Center
Human Vaccines Project

Completed

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults (KIRV)

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1

United States
GiveWell
New Incentives; All Babies are Equal Initiative

Completed

Evaluation of an Infant Immunization Encouragement Program in Nigeria

Hepatitis B | Measles | Pertussis | Tetanus | Diphtheria | Tuberculosis | Pneumonia, Bacterial | Yellow Fever | Polio | Rotavirus Infections | Haemophilus Influenzae Type b Infection

Nigeria
GlaxoSmithKline

Completed

Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Argentina
Swedish Institute for Infectious Disease Control

Unknown

Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease (Sero 2007)

Hepatitis B | Measles | Pertussis | Rubella | Mumps | Tetanus | Diphtheria | Polio | Haemophilus Influenzae Type B

Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Colombia, Costa Rica
Shantha Biotechnics Limited

Completed

Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type B

India
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Vietnam
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

India
NPO Petrovax

Completed

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza Epidemic

Russian Federation
Evidation Health
University of Washington; Biomedical Advanced Research and Development Authority and other collaborators

Completed

Home Testing of Respiratory Illness

Respiratory Tract Infections | Influenza A | Influenza Type B | Respiratory Viral Infection | Influenza -Like Illness

United States
Marshfield Clinic Research Foundation
University of Wisconsin, Madison; Centers for Disease Control and Prevention

Completed

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

Influenza A Virus Infection | Influenza B Virus Infection | Immune Response to Influenza Vaccine

United States
Novo Nordisk A/S

Completed

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

India, Morocco, South Africa, Oman
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

Spain
American Thrombosis and Hemostasis Network
Takeda; CSL Behring; Octapharma

Completed

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Hemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without Inhibitor

United States
Novo Nordisk A/S

Withdrawn

Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
QIAGEN Gaithersburg, Inc

Completed

Collection and Testing of Respiratory Samples

Respiratory Syncytial Virus Infections | Influenza A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infection Due to Human Parainfluenza Virus 1 | Parainfluenza Type 2 | Parainfluenza Type 3 | Parainfluenza Type 4 | Human Metapneumovirus A/B | Coxsackie Virus/Echovirus | Adenovirus Types B/C/E | Coronavirus Subtypes 229E and other conditions

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

Influenza A Virus Infection | Influenza B Virus Infection

China
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Dx

Recruiting

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Dx

Completed

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

COVID-19 | Influenza A | Influenza Type B

United States

Clinical Trials on Haemophilus Influenza Type b

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations